Alkermes (Alkermes) Price-to-Tangible-Book

: 3.56 (As of Today)

View and export this data going back to 1991. Start your Free Trial

As of today (2024-04-19), Alkermes's share price is $23.86. Alkermes's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $6.69. Hence, Alkermes's Price to Tangible Book Ratio of today is 3.56.

The historical rank and industry rank for Alkermes's Price-to-Tangible-Book or its related term are showing as below:

ALKS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.42 Med: 4.58 Max: 13.2
Current: 3.57

During the past 13 years, Alkermes's highest Price to Tangible Book Ratio was 13.20. The lowest was 3.42. And the median was 4.58.

ALKS's Price-to-Tangible-Book is ranked worse than
69.5% of 872 companies
in the Drug Manufacturers industry
Industry Median: 2.285 vs ALKS: 3.57

A closely related ratio is called PB Ratio. As of today, Alkermes's share price is $23.86. Alkermes's Book Value per Sharefor the quarter that ended in Dec. 2023 was $7.20. Hence, Alkermes's P/B Ratio of today is 3.31.

Alkermes Price-to-Tangible-Book Historical Data

The historical data trend for Alkermes's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

3.55

3.42

3.70

4.33

4.14

Alkermes Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book																4.33	4.92	4.15	3.47	4.14

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alkermes Price-to-Tangible-Book Distribution

For the Drug Manufacturers industry and Healthcare sector, Alkermes's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Alkermes's Price-to-Tangible-Book falls into.

Alkermes Price-to-Tangible-Book Calculation

Alkermes's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	23.86	/	6.693
	=	3.56

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Alkermes Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Alkermes's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Alkermes (Alkermes) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (NAS:ALKS) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

8AK:Germany

Address

1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6

Website

https://www.alkermes.com

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Executives

Cato T Laurencin	director	C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
Christian Todd Nichols	officer: SVP, Chief Commercial Officer	852 WINTER STREET, WALTHAM MA 02451
Nancy Wysenski	director	2200 SUNBURST STREET, CHATSWORTH CA 90401
Daglio David Angelo Jr.	director	ALKERMES, 852 WINTER STREET, WALTHAM MA 02451
Christopher I Wright	director	C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Michael J Landine	officer: SVP, Corp Dev., Alkermes, Inc.	88 SIDNEY ST, CAMBRIDGE MA 021394136
Richard F Pops	director, officer: Director and CEO, Alkermes plc	10555 SCIENCE CENTER DR, SAN DIEGO CA 92121
Shane Cooke	officer: President, Alkermes plc	TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Blair Curtis Jackson	officer: EVP, Chief Operating Officer	852 WINTER STREET, WALTHAM MA 02451
Snyderman Nancy Lynn Md	director	37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Craig C. Hopkinson	officer: SVP, Med Dev/Med Affairs, CMO	852 WINTER STREET, WALTHAM MA 02451
Emily Peterson Alva	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Iain Michael Brown	officer: VP, Finance & CAO	14 ROYALSTON AVENUE, WINCHESTER MA 01890
Brian P Mckeon	director	IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
David Joseph Gaffin	officer: SVP, CLO, Alkermes, Inc.	852 WINTER STREET, WALTHAM MA 02451